3
Announcements
Trials
Browse
Landscape
Status
Terminated
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Multiple Chronic Conditions
1
Lung Neoplasms
1
Lung Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
103
Pemetrexed
96
pembrolizumab
78
Docetaxel
78
Cisplatin
72
Paclitaxel
70
Erlotinib Hydrochloride
50
Gemcitabine
48
Radiotherapy
42
Nivolumab
35
Bevacizumab
35
atezolizumab
24
Radiosurgery
24
durvalumab
20
Cyclophosphamide
17
130-nm albumin-bound paclitaxel
15
Vinorelbine
14
Taxes
14
Radiation
14
Etoposide
13
Ipilimumab
12
Albumin-Bound Paclitaxel
12
avelumab
11
Drug Therapy
10
Cetuximab
10
spartalizumab
9
Sorafenib
9
trametinib
8
osimertinib
8
capmatinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Non-Small-Cell Lung
×
Patient Reported Outcome Measures
×
Clear all
NCT03053297
2018-02-08
PANORAMA
AstraZeneca
Terminated
89 enrolled
NCT02405247
2015-07-31
TAURAS
AstraZeneca
Terminated
400 enrolled